Comparative Bioavailability of Myfenax® and CellCept® in Kidney Transplant Patients
Status:
Terminated
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to further investigate how much of the drug substance
"mycophenolate mofetil" can be found in the blood of patients with kidney or renal
transplants when treated with Myfenax® or CellCept®. Additionally, the safety and side
effects of the two products will be compared. All information already available on these
products indicates that the safety profiles of the two products will be the same.
Phase:
Phase 4
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Pharmaceutical Industries